Non-conventional therapy of lethal pneumonia symptoms and viral activity of sars-cov-2 during cov-id-19 infection using bee venom compound, melittin : ahypothesis
By: Tiwari, Ruchi
.
Contributor(s): Tiwari, Gaurav.
Publisher: Mumbai Indian Journal of Pharmaceutical Science 2021Edition: Vol.53(4), April.Description: 14-20p.Subject(s): PHARMACEUTICSOnline resources: Click here
In:
Pharma timesSummary: Suggested cell entry mechanisms of SARS-CoV-2 are binding of S1 protein present on spikes of SARS-CoV-2 with the cell surface of
hACE2 and S-protein priming by the serine protease, Transmembrane Serine Protease 2 (TMPRSS2) and cysteine protease, Cathepsin
B and L (Cat B/L). Melittin is the primary constituent of Apis mellifera, the European honeybee poison which acts as an anti-cancer,
anti-microbial, anti-viral, anti-diabetic and anti-inflammatory agent. Reports suggested that Melittin can directly lyse the viral membrane,
may act as Serine Protease inhibitor and is able to inhibit aggregation of membrane proteins and thus can reduce the pneumonia-like
symptoms during SARS-CoV-2 infection. Herein, we discuss the potential use of Melittin to subside pneumonia-like symptoms and act
as an anti-viral agent in the early stages of COVID-19 treatment.
| Item type | Current location | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2022-0876 |
Suggested cell entry mechanisms of SARS-CoV-2 are binding of S1 protein present on spikes of SARS-CoV-2 with the cell surface of
hACE2 and S-protein priming by the serine protease, Transmembrane Serine Protease 2 (TMPRSS2) and cysteine protease, Cathepsin
B and L (Cat B/L). Melittin is the primary constituent of Apis mellifera, the European honeybee poison which acts as an anti-cancer,
anti-microbial, anti-viral, anti-diabetic and anti-inflammatory agent. Reports suggested that Melittin can directly lyse the viral membrane,
may act as Serine Protease inhibitor and is able to inhibit aggregation of membrane proteins and thus can reduce the pneumonia-like
symptoms during SARS-CoV-2 infection. Herein, we discuss the potential use of Melittin to subside pneumonia-like symptoms and act
as an anti-viral agent in the early stages of COVID-19 treatment.
Click on an image to view it in the image viewer
There are no comments for this item.